Table 1 Comparison of clinical and laboratory features between AML patients with and without DNMT3A mutations.

From: Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations

Clinical characters

DNMT3Awt (n = 741)

DNMT3Amut (n = 143)

P value

Sex

  

0.098

 Female

338

76

 

 Male

403

67

 

Age

48 (12–84)

53 (17–82)

<0.001

Laboratory data

 WBC, ×109 /L

15.4 (0.16–627.8)

34.6 (0.49–315.1)

<0.001

 Hb, g/dL

8.1 (2.4–15)

8.6 (3.7–15.3)

0.024

 Platelet, ×109 /L

42 (3–1017)

60 (2–514)

<0.001

 PB blast (%)

42 (0–99)

35 (0–99)

0.876

 LDH (U/L)

680 (96–15000)

653 (111–7177)

0.944

Cytogenetics

 Favorable

123 (16.6)

2 (1.4)

<0.001

 Intermediate

534 (72.1)

133 (93.0)

<0.001

 Unfavorable

77 (10.4)

5 (3.5)

0.009

 NA

7 (1.0)

3 (1.4)

0.233

2022 ICC

 t(8;21)(q22;q22.1)/RUNX1::RUNX1T1

87 (11.7)

1 (0.7)

<0.001

 inv(16)(p13.1q22) or t(16;16)

(p13.1;q22)/CBFB::MYH11

38 (5.1)

1 (0.7)

0.018

 t(9;11)(p21.3;q23.3)/MLLT3::KMT2A

12 (1.6)

0 (0.0)

0.125

 other KMT2A rearrangements

27 (3.6)

0 (0.0)

0.020

 t(6;9)(p22.3;q34.1)/DEK::NUP214

5 (0.7)

0 (0.0)

0.325

 inv(3)(q21.3q26.2) or t(3;3)

(q21.3;q26.2)/GATA2; MECOM(EVI1)

11 (1.5)

0 (0.0)

0.125

 t(9;22)(q34.1;q11.2)/BCR::ABL1

3 (0.4)

1 (0.7)

0.818

 CEBPAbZIP-inf

107 (14.4)

5 (3.5)

<0.001

 Mutated NPM1

99 (13.4)

72 (50.3)

<0.001

 Mutated TP53

34 (4.6)

2 (1.4)

0.077

 AML with myelodysplasia-related gene mutations

142 (19.2)

27 (18.9)

0.937

 AML with myelodysplasia-related cytogenetic abnormalities

42 (5.7)

7 (4.9)

0.712

 AML, NOS

134 (18.1)

27 (18.9)

0.821

2022 WHO

 RUNX1-RUNX1T1 fusion

87 (11.7)

1 (0.7)

<0.001

 CBFB-MYH11 fusion

38 (5.1)

1 (0.7)

0.018

 DEK-NUP214 fusion

5 (0.7)

0 (0.0)

0.325

 BCR-ABL1 fusion

3 (0.4)

1 (0.7)

0.818

 KMT2A rearrangement

39 (5.3)

0 (0.0)

0.005

 MECOM rearrangement

11 (1.5)

0 (0.0)

0.143

 NUP98 rearrangement

13 (1.8)

0 (0.0)

0.111

 CEBPA mutation

112 (15.2)

6 (4.2)

<0.001

 NPM1 mutation

99 (13.2)

72 (50.3)

<0.001

 Myelodysplasia-related

163 (22.0)

25 (17.5)

0.227

 AML, defined by differentiation

171 (23.1)

37 (25.9)

0.470

ELN-2022

 Favorable

285 (38.5)

43 (30.1)

0.057

 Intermediate

176 (23.8)

56 (39.2)

<0.001

 Unfavorable

280 (37.8)

44 (30.8)

0.111

CR1

562 (75.8)

106 (74.1)

0.662

Relapse (CR1 no HSCT)

238 (32.1)

58 (40.6)

0.102

Allo-HSCT

314 (42.4)

64 (44.8)

0.598

 CR1

154 (20.8)

29 (20.3)

0.892

 CR2

66 (8.9)

8 (5.6)

0.190

 Others

94 (12.7)

27 (18.9)

0.048

  1. Allo-HSCT allogeneic hematopoietic stem cell transplantation, CR complete remission, ELN European LeukemiaNet, Hb hemoglobin, PB peripheral blood, ICC International Consensus Classification, LDH lactate dehydrogenase, NA not available, WBC white blood cell, WHO World Health Organization.
Back to article page